Effective approaches in conquering chemoresistance of glioblastoma: potential for nanoformulations
- 21 April 2025
- journal article
- research article
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (3) , 960-982
Abstract
Glioblastoma Multiforme is an aggressive and complex cancer affecting mostly elderly patients above the age of 60 years. Originally classified as the fourth stage of glioma, it has an abysmal prognosis along with limited therapeutic options. Surgical removal of tumors, radiotherapy, and chemotherapy are prevalent treatment strategies with numerous therapeutic obstacles, including undefined boundary of tumor mass leaving traces even after excision, chances of secondary cancer formation, and presence of blood–brain barrier. These blood–brain and blood–brain tumor barriers actively restrict the permeability of many molecules from blood circulation to enter the central nervous system. Therefore, many conventional antineoplastic drugs fail to reach the tumor periphery except temozolomide. Meanwhile, active stem cells in the tumor microenvironment, genetic mutation inducing tumor growth, and epigenetic pattern alteration make this cancer chemoresistant. Our review delineates the recent approaches to resensitize the existing clinical drugs through specifically designed nanoformulations. Nanoparticles with modified physiological characteristics and modified through technological parameters can reduce the tumor's stemness, which increases tumor cells' apoptosis rate. Moreover, these nanoparticles can efficiently traverse the blood–brain barrier and escape from endosomal degradation with minimum toxicological impact. Overall, this review discusses the cancer chemoresistance phenomena and related pathways and highlights the potential of nanoformulation in reversing chemoresistance. Also, the existing limitations of this unique approach and suggestions are discussed at the end of the article, which may facilitate the identification of new directions for advancement of the nanoparticle-mediated reversal of chemoresistance. Graphical AbstractKeywords
Funding Information
- Council of Scientific and Industrial Research, India (27(0347)/19/EMR-II))
- Anusandhan National Research Foundation (JCB/2019/000008)
- Indian Council of Medical Research (5/13/53/2020-NCD-III)
This publication has 159 references indexed in Scilit:
- A Nanoparticle Carrying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Improves SurvivalACS Nano, 2014
- Control of glioma cell death and differentiation by PKM2–Oct4 interactionCell Death & Disease, 2014
- Protective Properties of Radio-Chemoresistant Glioblastoma Stem Cell Clones Are Associated with Metabolic Adaptation to Reduced Glucose DependencePLOS ONE, 2013
- Nanomedicine therapeutic approaches to overcome cancer drug resistanceAdvanced Drug Delivery Reviews, 2013
- Multidrug resistance: Physiological principles and nanomedical solutionsAdvanced Drug Delivery Reviews, 2013
- Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumorAdvanced Drug Delivery Reviews, 2013
- Multiple Drug Resistance Mechanisms in CancerMolecular Biotechnology, 2010
- Enhanced MDR1 Expression and Chemoresistance of Cancer Stem Cells Derived from GlioblastomaCancer Investigation, 2009
- Targeting cancer with small molecule kinase inhibitorsNature Reviews Cancer, 2009
- Small-molecule inhibitors of protein–protein interactions: progressing towards the dreamNature Reviews Drug Discovery, 2004